Covid19 is not the first pandemic we will ever deal with and certainly will not be the last one, but it is incredibly important that we come together as a nation and as a planet to get ahead of this, address it, ad, you know, come up with remedy for it. If we think about the basis of Global Health security, it is a threepronged approach containment, mitigation, and then treatment. This is the third hearing that i am chairing on this subject. The first focused on the containment strategy. That was the first hearing that congress held. The conclusion of that was the initial strategy of trying to contain this disease with travel bands, etc. , was likely not going to be successful. Very difficult, and i think what china did was ambitious. About us some time that most of us in the Public Health world recognize that we would likely see in community cases, it would be difficult to stop the spread of this disease. The second hearing we had was on mitigation, largely looking at testing, this wa
Will discuss progress made in the work to combat hiv. One of the speakers is dr. Anthony felty, the head of the allergy and Infectious Diseases department. It should get underway shortly here on cspan. Once again, we are waiting for the start of a program of Health Officials working to combat hiv. We would hear from dr. Anthony fauci, the head of the national of allergies and Infectious Diseases. In the meantime, the city press in africa is reporting that preparatory work is well underway to license an hiv vaccine in south africa. If all goes well, the followup trials are set to begin january, 2017, and could be used for general use by 2019. This was revealed by glenda gray at the hiv research for Prevention Conference that is taking place in cape town. Waiting for the start of this gathering of Health Officials, a discussion on progress made in creating a vaccine to combat hiv. All of the panelist, we understand, are in the room to ,y clipping dr. Anthony fauci head of the National In
Two different things. When you are looking at hearings, you will see more hearings in the senate that look like what you have been seeing in the house over the last several years. Administration officials being called from various departments and agencies to essentially get byed over the coals republican senators who are going to be chairman of these committees for the first time. You are going to see more critical hearings and hearings that are built around topics that are critical of the administration. In terms of legislation, you are probably going to see more markups and more consideration of bills at the Committee Level and when they come out of the last couple in the of years, bills of come out of committee and then sort of disappeared in a number of cases. What mcconnell is at least saying and what he said last coat newsnew conference that if a bill comes out on a bipartisan basis, somebody might actually see it on the floor. You also mentioned an open amendment process. How li
We are also very concerned about the longterm issues of the registration of these products, in terms of the affordability of these products. This is especially important because this is unfortunately something that is going to keep coming back. We are not sure our organization in the future will be able to respond. Need access to these products in the future. We need to take steps now to ensure that we can safeguard the longterm access. In terms of the vaccines, we very much worth thinking about t and the important of importance of vaccination protection. The stops pull a all in terms of really accelerating the trials and in terms of accelerating the production and recognizing that both for the companies and the donors and that this would entail certain risks in the short term and the medium term. We certainly take a very pragmatic approach to that. Approach of the structure that has been put forth. One is certainly around the price of the vaccines, which has not been specified actuall
/PRNewswire/ The "Emerging Landscape of Targeted Protein Degradation Therapeutics" report has been added to ResearchAndMarkets.com s offering. Advancing.